Kurve Therapeutics
Bypassing the Blood-Brain Barrier
Analytics
Rialto Markets
08/03/2022
08/03/2023
$580
$50,000,000
$580
Equity - Common
RegA+
Series A
$5.80
$291,787,299
Lynnwood, Washington
Healthcare & Pharmaceuticals
HealthTech
B2B
Medium
High
Balance Sheet
|
Cash and Cash Equivalents |
$373,804 |
|
Accounts and Notes Receivable |
$15,000 |
| Total Assets |
$640,574 |
|
Accounts Payable & Accrued Liabilities |
$28,331 |
|
Long Term Debt |
$507,500 |
|
Total Liabilities |
$606,726 |
|
Total Stockholders' Equity |
$33,848 |
| Total Liabilities and Equity |
$640,574 |
Statement of Comprehensive Income Information
|
Total Revenues |
$70,700 |
|
Costs & Expenses Applicable to Rev |
$128,344 |
| Net Income |
$-65,427 |
|
Earnings Per Share - Basic |
$0.00 |
|
Earnings Per Share - Diluted |
$0.00 |
Upgrade to gain access
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Ratings 
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Analyst Report
No company has been able to develop an FDA-approved treatment that stops Alzheimer’s in its tracks. Kurve Therapeutics has the potential to change that with its potentially groundbreaking device. But its long road to FDA approval and its inexperienced team may threaten the company’s survival.